Biophysical Therapeutics, based in Delaware, has introduced its new consumer longevity skincare brand, IF1. The company is currently accepting pre-orders for its first product, an anti-aging skin moisturizer priced at $120. Only 500 units are available in the initial production run, which can be purchased at www.IF1.skin.
Read More
The moisturizer integrates advanced longevity science and is designed to contribute to the funding of Biophysical Therapeutics' drug research programs targeting cancer, age-related diseases such as Alzheimer's, and the aging process itself. Founded in 2022 by Dr. Michael Forrest, who has a Ph.D. in computer science and a background in biochemistry from Cambridge University, the company is advised by Professor George Church of Harvard Medical School.
Biophysical Therapeutics specializes in computational biology, particularly biophysical modeling, which involves mathematical modeling of biological systems. The company stands out for having developed new drugs that have been validated through experimental research and are protected by patents.
The science behind their moisturizer is based on findings that species with higher levels of IF1 protein exhibit longer lifespans. Research has demonstrated that increasing the IF1 protein in mice can effectively reduce aging markers.
The anti-aging skincare market, currently valued at $70 billion and expanding, presents a promising opportunity for the IF1 brand, which leverages pioneering research to gain a foothold in this competitive field. According to economists, the potential economic benefit of extending life expectancy in the U.S. could amount to $38 trillion annually.
Dr. Forrest stated, "Our IF1 brand brings leading-edge anti-aging science to skincare. This is just part of our mission to save, improve, and extend lives at mass scale."
The IF1 anti-aging moisturizer is available for pre-order exclusively at www.IF1.skin.